Review Article

High-Flow Nasal Cannula in Hypercapnic Respiratory Failure: A Systematic Review and Meta-Analysis

Table 3

Characteristics of the participants.

Authors, yearAge (years)Gender (male/total)APACHE II scoreRespiratory rates (times/minute)pHPaO2 (mmHg) or PaO2/FiO2(mmHg)PaCO2 (mmHg)Respiratory support duration (days or hours)
HFNCNIVHFNCNIVHFNCNIVHFNCNIVHFNCNIVHFNCNIVHFNCNIVHFNCNIV

RCTs
Jing et al., 201877.4 ± 6.873.9 ± 6.9?/22?/2011.8 ± 3.110.42.518.3 ± 3.519.2 ± 4.17.46 ± 0.047.44 ± 0.06235.8 ± 77.0250.8 ± 75.852.4 ± 6.453.7 ± 8.62.73 ± 1.954.07 ± 4.40
Yu et al., 201962.4 ± 10.163.5 ± 11.224/3621/3628.6 ± 2.828.5 ± 3.432 ± 4.433 ± 4.37.26 ± 0.037.26 ± 0.0356.84 ± 2.7756.92 ± 2.8973.56 ± 6.973.5 ± 6.23
Wang et al., 201971.26 ± 7.3972.85 ± 6.6513/2312/2018.35 ± 2.1918.9 ± 2.5930.91 ± 2.1330.35 ± 2.687.23 ± 0.197.24 ± 0.0257.17 ± 5.6859.55 ± 6.4867.13 ± 4.2566.05 ± 3.037.96 ± 1.726.8 ± 1.26
Cong et al., 201966.91 ± 7.3867.88 ± 8.3848/8450/487.25 ± 0.087.27 ± 0.0953.10 ± 16.2254.08 ± 15.3372.11 ± 16.3172.91 ± 16.4110.02 ± 5.119.55 ± 4.78
Tan et al, 202068.4 ± 9.371.4 ± 7.827/4423/4214 (11–18.8)13 (10.8–16)18 (16–23)21 (16–26)7.48 (7.42–7.51)7.45 (7.40–7.49)239.2 ± 47.0229.3 ± 42.050.5 (48–57.8)53 (48.8–61.3)83.9 ± 33.170.9 ± 30.6
Papachatzakis et al., 202076 ± 13.478.1 ± 8.110/209/2021.6 ± 8.919.6 ± 6.17.1 ± 0.17.1 ± 0.176.4 ± 28.965.2 ± 12.960.4 ± 9.962.1 ± 10.32 ± 12 ± 9
Cohort studies

Lee et al., 201873 (68–79)77 (71–70)28/4429/4424 (20–28)24 (22–29)7.32 ± 0.287.31 ± 0.29134.8 ± 7.3134.5 ± 7.556.4 ± 10.152.6 ± 8.87 (5–10)8 (6–10)
Sun et al., 201973.2 ± 9.070.4 ± 7.424/3930/4318.4 ± 2.717.3 ± 3.428.1 ± 3.327.0 ± 3.57.31 (7.29–7.33)7.30 (7.28–7.32)138.2 ± 6.6140 ± 6.656 (53–62)59 (55–62)5 (4–7)6 (5–8)

distinguishes the two indicators of the variable. For example, “day” was chosen by Jing et al. (the first RCT in the table) in their study to measure the respiratory support duration, while Tan et al. (the fifth RCT in the table) prefer “hours” to be the measurement.